20260331-招银国际-时代天使-06699.HK-Earnings_beat_with_strong_overseas_momentum_5页_755kb

Angelalign (6699 HK) Summary

Core Content and Key Highlights

Angelalign, listed on the Hong Kong Stock Exchange under ticker 6699 HK, reported strong financial results for FY25, with revenue growing by 37.8% YoY to US$370 million and attributable net profit increasing by 134.7% YoY to US$28 million, both exceeding expectations. This performance was driven by rapid overseas expansion and continued market share gains in the domestic market.

Main Points

• Revenue Growth: FY25 revenue reached US$370 million, with 48.1% YoY growth in case shipments to 532,400.
• Profitability: Attributable net profit rose 134.7% YoY to US$28 million, with adjusted net profit at US$44 million.
• Overseas Business: Overseas revenue increased 102.5% YoY to US$163 million, with case volumes up 82.1% YoY to ~256,200. The adjusted operating loss narrowed by 64% YoY to US$11 million.
• Domestic Performance: Domestic revenue grew 10.1% YoY to US$207 million, with case shipments rising 26.3% YoY to ~276,200. Gross profit margin improved by 2ppts to 65%, indicating strong production efficiencies and scale benefits.
• IP Litigation: Legal costs are expected to increase in 2026E, potentially affecting profitability and growth.
• Outlook: The company expects 21.4% YoY revenue growth in 2026E, but net margin will decline from 7.7% to 7.0% due to capacity ramp-up and litigation expenses.

Financial Performance Overview

Valuation and Target Price

• Target Price: HK$91.89, derived from SOTP valuation.
• Valuation Breakdown:
  • Domestic business: HK$23.1 per share, 25.2% of total valuation.
  • Overseas business: HK$48.5 per share, 52.8% of total valuation.
  • Net cash: HK$20.2 per share, 22.0% of total valuation.
• Total Valuation (HK$ mn): 15,692.
• Shareholding Structure:
  • CareCapital Orthotech Limited: 51.1%
  • Shore Lead Limited: 12.6%

Earnings Revision

Market and Peer Comparison

• Peer Comparison (Fig 1):

  • Alcon (ALC US): P/E (2026E) = 21.6, P/S (2026E) = 3.4
  • Align Technology (ALGN US): P/E (2026E) = 15.7, P/S (2026E) = 3.0
  • Straumann (STMN SW): P/E (2026E) = 26.9, P/S (2026E) = 4.8
  • Stryker (SYK US): P/E (2026E) = 22.2, P/S (2026E) = 4.7
  • Boston Scientific (BSX US): P/E (2026E) = 20.3, P/S (2026E) = 4.7
  • Dexcom (DXCM US): P/E (2026E) = 26.6, P/S (2026E) = 4.9
  • STAAR Surgical (STAA US): P/E (2026E) = 42.1, P/S (2026E) = 3.1

• Overall Average P/E (2026E): 24.1

• Overall Average P/S (2026E): 4.9

Share Performance

Analyst Recommendations

• Rating: BUY
• Target Price: HK$91.89
• Previous Target Price: HK$86.47
• Upside/Downside: 22.8%

Risk and Considerations

• IP Litigation: Expected to increase in 2026E, potentially impacting profitability and overseas growth.
• Margin Pressures: Ramp-up costs of new facilities and increased litigation expenses may affect short-term margins.
• Global Expansion: Localized supply chain investments in Brazil, Southeast Asia, and the US are critical for long-term growth.

Conclusion

Angelalign is demonstrating strong growth and improved profitability, with overseas expansion as the main growth driver. Despite the potential for margin pressure in 2026E, the company is expected to maintain positive momentum. The BUY rating reflects optimistic outlook and strong earnings revisions. Investors should be aware of ongoing legal challenges and market dynamics as they consider the company's future performance.